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Table 1. Factors Predictive of Neutrophil and Platelet Engraftment in
Multivariate Analysis of Graft/Recipient Characteristics
Multivariate Model
Neutrophil
engraftment
(p-value)
Platelet
engraftment
(p-value)
Pre-cryopreservation CD341 (0.0046) Recipient ethnicity
(0.0052)
Recipient CMV
(0.0138)
TNC (0.0173)
CFU (0.0337) CFU (0.0324)
Unit Sex (0.0393)
Post-thaw CFU (\0.0001) CFU (\0.0001)
CD34 (0.0013) HLA match (0.0117)
HLA match
(0.0065)
Recipient ethnicity
(0.0135)
Overall Post thaw CFU
(\0.0001)
Recipient ethnicity
(0.0063)
Unit Sex (0.0131) Post thaw CFU (0.002)
HLA match (0.0186)
Post thaw CD34 (0.02)
AXP Stem Cell Recovery
Volume
(mL)
Mean Post-
Processing
TNC
(108)
TNC
Percent
Recovery
(%)
Mean Post-
Processing
MNC
(108)
MNC
Percent
Recovery
(%)
Mean 72.93 9.94 96.19 4.05 98.65
Standard
Deviation
18.10 4.43 11.87 1.59 9.16
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STEM CELL RECOVERY FOLLOWING IMPLEMENTATION OF AN AUTO-
MATED CORD BLOOD PROCESSING SYSTEM IN A HIGH VOLUME LABO-
RATORY
Rosenthal, J.1, Brown, H.L.2, Harris, D.T.3 1City of Hope, Duarte, CA;
2CBR Systems, Inc., San Bruno, CA; 3University of Arizona, Tucson,
AZ.
Background: Many cord blood unit (CBU) processing facilities
are transitioning to automated systems to standardize methods
and decrease human error. The AutoXpress Platform (AXP)
is an automated, functionally closed, sterile CBU processing system.
When placed within the AXP device and centrifuged, whole blood is
separated into composite cell populations and the TNC fraction is
separated and automatically delivered into a blow-molded freezing
bag at a uniform volume of 21 mL. Objective: This study evaluated
the use of the AXP system in a directed donation family cord blood
bank, targeted at producing consistently high TNC and MNC re-
covery rates regardless of variability in collection volume.
Methods: CBU were collected between 12/5/2006 and 2/24/2007
from 1414 consenting mothers who elected to preserve and bank
CBU at Cord Blood Registry (CBR). Collection kits were provided
at enrollment, and after delivery, cord blood was collected from the
umbilical cord and transported to CBR’s processing facility in Tuc-
son, Arizona. During the study period, CBU arriving at the CBR
laboratory were allocated to either ficoll or AXP processing based
on the volume, age, and the degree of clotting. Units processed us-
ing AXP had a volume of 40–130 mL, an age of less than 48 hours
since collection, and a clotting score of 0 to 21 (based on an internal
scale). TNC and MNC were measured both pre- and post-process-
ing, using the Sysmex analyzer. Results: The mean age of CBU ar-
riving at the laboratory was 23.59 hours, and the mean collection
volume was 72.93 mL (618.10 mL). The mean TNC count post-
processing was 9.94  108, the TNC percent recovery was
96.19%, and the mean MNC percent recovery was 98.65%. Con-
clusions: AXP automated processing provides consistently high
TNC and MNC recovery rates, which has important implications
for stem cell dose if the sample is used in transplant. Because limited
cell dose is frequently cited as an obstacle to CBU transplantation,
processing results could impact the usability of each sample. Be-
cause family cord blood banks process all samples, regardless of col-
lection volume, percent recovery becomes particularly important in
evaluating the differences between processing centers. The AXP
system yields the highest published cell recovery rate to date and
can be easily integrated into a CBU processing center such that it
decreases the labor and time required for CBU processing while
maintaining MNC recovery of greater than 98%.109
IgH GENE REARRANGEMENTS IN PBPC MONONUCLEAR CELLS DOES
NOT INFLUENCE SURVIVAL OR RELAPSE FOLLOWING AUTOLOGOUS
TRANSPLANTATION FOR B-CELL LYMPHOPROLIFERATIVE DISEASES
Ho, J.1, Yang, L.2, Benihashemi, B.1, Martin, L.2, Halpenny, M.2,
McDiarmid, S.1, Huebsch, L.1, Sabloff, M.1, Atkins, H.1, Bence-
Bruckler, I.1, Giulivi, A.2, Allan, D.1 1University of Ottawa, Ottawa,
ON, Canada; 2Canadian Blood Services, Ottawa, ON, Canada.
Background: Relapsed disease remains a major obstacle follow-
ing autologous hematopoietic stem cell transplantation (HSCT) for
non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM).
Studies regarding the role of residual tumour cells collected in au-
tografts in earlier relapse and reduced survival have been inconclu-
sive. The impact of residual disease detected by sensitive molecular
methods in autologous PBPCs remains uncertain and is addressed
in this study. Methods: Patients undergoing autologous HSCT
for NHL and MM at our institution between June 2001 and January
2006 were enrolled (n 5 158). Aliquots of freshly collected PBPC
collections were assessed for the presence of clonal IgH gene rear-
rangements using qualitative semi-nested PCR. Patients with de-
tectable clonal IgH gene rearrangements were designated
‘‘positive’’ and compared with ‘‘negative’’ patients without detect-
able IgH gene rearrangements. Survival, progression-free survival,
and time to next treatment were determined for all patients. All out-
comes were compared using the method of Kaplan and Meier.
Results: In comparison to patients with ‘‘positive’’ PBPC grafts,
patients ‘‘negative’’ for detectable disease had no improvement in
overall survival for MM (p5 0.91) and for NHL (p5 0.82). Further
analysis based on tissue histology in patients with NHL revealed no
significant difference in overall survival between patients with ‘‘pos-
itive’’ grafts compared with ‘‘negative’’ PBPC collections (aggressive
histology NHL, p5 0.74; indolent NHL, p5 0.29). There was also
no significant improvement in progression-free survival among pa-
tients with NHL (p 5 0.85) or MM (p 5 0.91). Conclusion: The
use of autologous PBPCs ‘‘negative’’ for contaminating tumour cells
does not lead to improved overall survival in MM or NHL. Further-
more, the absence of detectable clonal IgH rearrangements using
sensitive PCR did not correlate with a reduction in progression-
free survival. Our results suggest that disease relapse cannot be ad-
equately explained by the reinfusion of PBPCs containing residual
tumour cells. It is possible that high dose chemotherapy regimens
used in autologous HSCT are not sufficiently eliminating residual
tumour burden in some patients, including those with ‘‘negative’’
PBPC collections. Taken together, our results suggest that strate-
gies aimed at removing tumour cells from autologous PBPC grafts
in patients with MM and NHL may have marginal benefit.110
ENHANCED NATURAL KILLER (NK) AND NK T CELL ACTIVATION, EX-
PANSION AND CYTOKINE PROTEIN PRODUCTION FOLLOWING EX-
VIVO ENGINEERING (EvE) OF PREVIOUSLY CRYOPRESERVED CORD
BLOOD (CB): POTENTIAL FOR CB NK AND NK T CELLS IN ADOPTIVE
CELLULAR IMMUNOTHERAPY (ACI)
Ayello, J., Sugarman, E., Day, N., Hochberg, J., Mar, B., Cairo, E., van
de Ven, C., Cairo, M.S. Columbia University, New York, NY.
CB is limited by the absence of available donor effector cells fol-
lowing UCBT. We demonstrated the immaturity of CB by reduced
Poster Session I 43expression and production of IL-15, IL-12 and IL-18 in activated
CB (Qian/Cairo, Blood, 1997; Lee/Cairo, Blood 1996; Satwani/
Cairo, Br J Haem, 2005) may contribute to diminished CB cellular
immunity and delayed immune reconstitution after UCBT.
NKCD3-/561 effector cells recognize target cells and express activat-
ing and inhibitory receptors. NKTCD31/561 cells may also play
a role in allograft and tumor cytotoxicity. We reported the ability
to EvE cryopreserved, thawed, recryopreserved, rethawed CB
with increased NKbright/dim subsets expressing KIRs and NCR
with enhanced in-vitro and in-vivo cytotoxicity (Ayello/Cairo.
BBMT, 2006). In this study, we compare 2 vs 7 d expansion and ac-
tivation of NK and NKT subsets expressing NKRs and the produc-
tion of IL-15, IL-18 and IFN-g. Rethawed CB cells were cultured
with anti-CD3, IL-2, IL-7 and IL-12; 2–7 days. CD3, CD16,
CD56, CD94, NKG2A, NKG2D, NKp46, KIR2DS4, KIR3DL1,
LAMP-1 and granzyme B expression were determined by flow cy-
tometry; IL-15, IL-18 and IFN-g protein by ELISA. Non-adherent
total cells were significantly increased (6.26 214  107 vs 5.86 57
 106, p\ 0.001) with no change in NKdim subset; but significant
increased NKT subset (71.8 6 6.0 vs 2.97 6 0.3%, p\ 0.001).
NKbright cells were decreased (3.3 6 1.1 vs 13.4 6 1.4%, p \
0.01); whereas, NKTbright subset was significantly increased (10.6
6 1.4 vs 0.7 6 0.1%, p \ 0.05). NK KIRdim/bright subsets were
not significantly increased, but NKT KIR3DL1dim subset was in-
creased (17.1 6 1.2 vs 1.1 6 0.5%, p\ 0.05). CD94/NKG2A ex-
pression was decreased (7.8 6 1.3 vs 22.7 6 1.0%, p \ 0.001.)
while CD94/NKG2D was increased (41.4 6 0.4 vs 23.7 6 2.0%,
p\ 0.001). NK and NKT KIR2DS4 subsets were increased (24.8
6 0.1 vs 3.1 6 0.4%, p\ 0.001; 19.0 6 0.6 vs 1.0 6 0.1%, p\
0.001, respectively), as well as CD107a (65.3 6 2.2 vs 12.95 6
1.5%, p\ 0.001), granzyme B (33.6 6 0.61 vs 25.8 6 1.79%, p\
0.01), and IL-18 and IFN-g protein production (730 6 4.7 vs 183
6 8.8 pg/ml, p\ 0.001; 37.3 6 7.6 vs 21 6 1.4 pg/ml, p\ 0.05).
In summary, CB MNC may be thawed at time of UCBT, recryopre-
served, rethawed, and activated for up to 7 d to yield increased NK
and NKT subsets with increased KAR expression (KIR2DS4,
CD94/NKG2D), NK activation (CD107a), and production of IL-
18 and IFN-g, suggesting that cryopreserved CB cells may be
EvE for potential use as ACI for DLI after UCBT.Results N 5 46 Values reported as Median (Range)
TNC
dose
 107/kg N
% Post-
thawTNC
Recovery
% Post-thaw
Viability
Days to
ANC . 500
Days to Plt
Engraftment
100 Day
Survival
1.7 (0.9–4.4) 46 96 (80–100) 99 (96–99) 18 (11–38) 49 (18–87) 65%
#1.5 19 21 (13–38) 63 (38–87) 77%
.1.5 27 16 (11–34) 37 (18–59) 57%111
LENALIDOMIDE DIRECTLY UPREGULATES NK (NATURAL KILLER) CELL
TRAIL AND GRANZYME B EXPRESSION: IMPLICATIONS FOR ADOPTIVE
NK CELL IMMUNOTHERAPY FOLLOWING ALLOGENEIC HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION (HCT)
Srivastava, S.1, Lundqvist, A.2, Berg, M.2, Yokoyama, H.2, Smith, A.2,
McCoy, J.P.2, Childs, R.2 1 Indiana University, Indianapolis, IN; 2Na-
tional Heart, Lung and Blood Institute, NIH, Bethesda, MD.
Immunomodulatory drugs have been shown to increase NK cell
numbers, and augment NK-cell dependent cytotoxicity in vivo.
Therefore, we investigated the effect of culturing fresh and ex-
panded NK cells in vitro with lenalidomide as a potential method
to augment their antitumor activity for subsequent adoptive infu-
sion following allogeneic HCT.
Methods: CD3-/CD561NK cells were isolated using immuno-
magnetic beads. Freshly isolated NK cells and in vitro expanded NK
cells (using irradiated EBV- LCL feeders and IL-2 over 10–14 days)
were treated with lenalidomide (0.4–40 mcg/ml) over 48–84 hours
in IL-2 (500 u/ml) containing media. The phenotype of lenalido-
mide treated NK cells and corresponding DMSO controls (vehicle
for lenalidomide) were characterized by flow-cytometry. The cyto-
toxicity of lenalidomide treated NK cells and corresponding
DMSO controls vs K562 cells and human renal cell carcinoma cells
was assessed by chromium release assay at varying effector to target
ratios (1.25:1 to 10:1). Results: Immunophenotypical analysis
showed in-vitro expanded NK cells treated with lenalidomide up-
regulated expression of granzyme-B; the MFI (mean fluorescence
intensity) in lenalidomide treated expanded NK cells compared to
untreated controls increased from 42726 3 to 51846 89. Similarly,
TRAIL surface expression increased in lenalidomide cultured NKcells; compared to controls, the MFI increased from 24.6 6 4.3 to
30.7 6 4.6 in lenalidomide treated expanded NK cells and 12.1 6
0.3 to 14.9 6 1.9 in lenalidomide treated fresh NK cells. Interest-
ingly, compared to controls, lenalidomide decreased NKG2D ex-
pression in expanded NK cells (MFI 128.6 6 31.6 to 70.7 6
22.8). Despite lenalidomide induced up-regulation of NK cell
TRAIL and granzyme B, cytotoxicity assays did not show significant
differences in killing of K562 cells or RCC lines by lenalidomide
treated vs untreated NK cells. Conclusion: Culturing fresh and ex-
panded NK cells in lenalidomide increased TRAIL and granzyme B
expression but did not enhance NK cell cytotoxicity of tumor tar-
gets. The decline in NKG2D expression in lenalidomide treated
cells may have offset any potential increase in NK cell cytotoxicity
expected to occur as a consequence of upregulating granzyme B
and TRAIL. Prior studies showing in vivo enhancement in NK
cell numbers and cytotoxicity after treatment with lenalidomide
may be related to the effects of this drug on other cellular popula-
tions which indirectly enhance NK cell function in vivo.112
PROCESSING CRYOPRESERVED LOW CELL DOSE UMBILICAL CORD
BLOOD FOR ADULT TRANSPLANTATION WITH MINIMAL MANIPULA-
TION AND CELL LOSS: A SINGLE INSTITUTION EXPERIENCE
Parthasarathy, M., Rodriguez, T., Smith, S., Lu, S., Stiff, P. Loyola
University Medical Center, Maywood, IL.
Hematopoietic Stem Cells from Umbilical Cord Blood (UCB)
are increasingly being used as an alternative to marrow or peripheral
blood stem cells in adults. Most Cord Blood Centers have recom-
mend a post thaw washing step to remove the cryoprotectant
DMSO (dimethylsulfoxide). As the total nucleated cell (TNC)
dose is considered one of the most important factors for successful
engraftment, a re-exploration of the need to wash thawed UCB cells
has been underway in many centers. To control for all UCB unit
variables (cryo bags, volumes etc.) and standardize thawing process
we established a methodology and made it our standard operating
procedure (SOP) after proper validation. Rather than washing,
our protocol uses a 4:1 dilution method that minimizes cell loss
and decreases DMSO concentrations to\ 2%. The diluent me-
dium consists of 8% human albumin in10% dextrose. Units are
thawed in a 37C water bath and then diluted over 12 minutes
with three rates set to deliver 10%, 30% and 60% of the volume
at 5%, 8% and 10% per minute respectively. After completion of di-
lution a sample is removed from the bag to perform viability, steril-
ity testing and TNC count and the cells are infused into the patients
over 15 minutes. Data was collected over 5 years (2002 to 2007) for
45 UCB transplants. All samples were negative for Sterility testing
and there were no adverse reaction during infusion. The recovery
and engraftment rates are as follows: Conclusion: The thaw dilu-
tion process without wash yielded a superior %TNC recovery
and %viability. All but one patient achieved ANC engraftment.
There were 7 (15%) early deaths due to infection. The ANC en-
graftment and 100 day survival was not significantly different be-
tween the 2 cell dose groups, but the platelet engraftment was
delayed in the group who received a TNC dose\1.5  107/kg.
We now target units with a cell dose of $ 1.5  107 TNC with
a minimum match of 4/6, but given the prompt ANC engraftment
seen, we continue to accept units of\1  107/kg processed in this
manner.
